Micro Cap Growth Fund
Daily price w/o sales charge as of 01/22/2021
$20.76
$0.45
YTD Returns w/o sales charge as of 01/22/2021
15.98%
Overall Morningstar RatingsSmall Growth
as of 12/31/2020
Morningstar rated the Lord Abbett Micro Cap Growth Fund class A share 5, 5 and 5 stars among 576, 505 and 381 Small Growth Funds for the overall rating and the 3, 5 and 10 year periods ended 12/31/2020, respectively.
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of micro and small-sized U.S. companies.
Fund Basicsas of 12/31/2020
- Total Net Assets
- $189.29 M
- Inception Date
- 05/01/2000
- Dividend Frequency
- Annually
- Fund Expense Ratio
- 1.31%
- Number of Holdings
- 87
- Minimum Initial Investment
- $1,500+
Fund Expense Ratio :
1.31%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
---|
w/o sales charge | 79.42% | 79.42% | 35.37% | 28.51% | 20.12% | 12.47% |
Lipper Category Avg. Small-Cap Growth Funds | 38.35% | 38.35% | 18.76% | 17.68% | 13.52% | - |
Russell Microcap® Growth Index | 40.13% | 40.13% | 14.04% | 13.08% | 11.57% | - |
w/ sales charge | 69.09% | 69.09% | 32.72% | 27.01% | 19.42% | 12.15% |
Fund Expense Ratio :
1.31%
Fund Expense Ratio :
1.31%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
---|
w/o sales charge | 79.42% | 79.42% | 35.37% | 28.51% | 20.12% | 12.47% |
Lipper Category Avg. Small-Cap Growth Funds | 38.35% | 38.35% | 18.76% | 17.68% | 13.52% | - |
Russell Microcap® Growth Index | 40.13% | 40.13% | 14.04% | 13.08% | 11.57% | - |
w/ sales charge | 69.09% | 69.09% | 32.72% | 27.01% | 19.42% | 12.15% |
Fund Expense Ratio :
1.31%
Returns with sales charges reflect a maximum sales charge of 5.75%.
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
TEN LARGEST HOLDINGS as of 12/31/2020View Portfolio
Holding | Assets |
---|---|
The Rubicon Project, Inc. | 3.6% |
Cerence Inc | 3.2% |
Calix Networks, Inc. | 2.7% |
Agilysys Inc | 2.5% |
Digital Turbine Inc | 2.5% |
Eidos Therapeutics Inc | 2.4% |
Cardlytics Inc | 2.0% |
Shockwave Medical Inc | 1.9% |
Pacific Biosciences of California, Inc. | 1.8% |
Telos Corp | 1.8% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 12/31/2020View Portfolio
Sector | Weighting |
---|
Sector | Weighting |
---|---|
Communication Services | |
Real Estate | |
Utilities | |
Not Classified | |
Consumer Discretionary | |
Consumer Staples | |
Energy | |
Financials | |
Health Care | |
Industrials | |
Information Technology | |
Materials |
INVESTMENT TEAM




Your Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
1.31%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
---|
w/o sales charge | 79.42% | 79.42% | 35.37% | 28.51% | 20.12% | 12.47% |
Lipper Category Avg. Small-Cap Growth Funds | 38.35% | 38.35% | 18.76% | 17.68% | 13.52% | - |
Russell Microcap® Growth Index | 40.13% | 40.13% | 14.04% | 13.08% | 11.57% | - |
w/ sales charge | 69.09% | 69.09% | 32.72% | 27.01% | 19.42% | 12.15% |
Fund Expense Ratio :
1.31%
Fund Expense Ratio :
1.31%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
---|
w/o sales charge | 79.42% | 79.42% | 35.37% | 28.51% | 20.12% | 12.47% |
Lipper Category Avg. Small-Cap Growth Funds | 38.35% | 38.35% | 18.76% | 17.68% | 13.52% | - |
Russell Microcap® Growth Index | 40.13% | 40.13% | 14.04% | 13.08% | 11.57% | - |
w/ sales charge | 69.09% | 69.09% | 32.72% | 27.01% | 19.42% | 12.15% |
Fund Expense Ratio :
1.31%
Returns with sales charges reflect a maximum sales charge of 5.75%.
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Year | Fund Returns | Russell Microcap® Growth Index |
---|
2020 | 79.42% | 40.13% |
2019 | 34.57% | 23.33% |
2018 | 2.74% | -14.18% |
2017 | 38.43% | 16.65% |
2016 | 2.07% | 6.86% |
2015 | -6.38% | -3.85% |
2014 | 10.83% | 4.30% |
2013 | 78.53% | 52.84% |
2012 | 2.35% | 15.17% |
2011 | -5.87% | -8.42% |
2010 | 33.77% | - |
2009 | 52.61% | - |
2008 | -46.45% | - |
2007 | 22.76% | - |
2006 | 25.37% | - |
2005 | 2.55% | - |
2004 | 25.89% | - |
2003 | 49.34% | - |
2002 | -30.97% | - |
2001 | 16.96% | - |
Year | Q1 | Q2 | Q3 | Q4 | Yearly Returns |
---|
2021 | - | - | - | - | 15.98% |
2020 | -24.28% | 47.61% | 17.48% | 36.65% | 79.42% |
2019 | 22.67% | 7.47% | -13.91% | 18.57% | 34.57% |
2018 | 5.24% | 15.77% | 10.08% | -23.39% | 2.74% |
2017 | 9.00% | 8.12% | 13.61% | 3.39% | 38.43% |
2016 | -13.70% | 6.01% | 14.49% | -2.55% | 2.07% |
2015 | 7.33% | 4.15% | -16.30% | 0.06% | -6.38% |
2014 | 7.92% | -6.53% | -6.55% | 17.58% | 10.83% |
2013 | 21.83% | 15.00% | 17.29% | 8.65% | 78.53% |
2012 | 17.67% | -9.76% | 1.32% | -4.87% | 2.35% |
2011 | 4.82% | 0.11% | -21.90% | 14.86% | -5.87% |
2010 | 6.60% | -8.74% | 15.08% | 19.49% | 33.77% |
2009 | -0.95% | 31.46% | 13.47% | 3.29% | 52.61% |
2008 | -23.22% | 4.46% | -5.93% | -29.02% | -46.45% |
2007 | 5.64% | 9.81% | 4.01% | 1.76% | 22.76% |
2006 | 17.15% | -9.83% | 1.22% | 17.25% | 25.37% |
2005 | -9.50% | 5.88% | 6.91% | 0.10% | 2.55% |
2004 | 12.33% | 1.65% | -11.11% | 24.03% | 25.89% |
2003 | -3.55% | 27.29% | 11.68% | 8.93% | 49.34% |
2002 | -0.18% | -12.74% | -21.79% | 1.33% | -30.97% |
2001 | 2.34% | 12.03% | -21.11% | 29.32% | 16.96% |
2000 | - | - | -4.83% | -19.30% | -30.76% |
Performance is shown for each quarter and each calendar year. Past performance is no guarantee of future results.
Growth of $10,000 as of 12/31/2020
The chart begins on the Fund's inception date of 05/01/2000.
Based on a hypothetical Class A share investment of $10,000 on 05/01/2000 without sales charge and includes the reinvestment of all distributions.
NAV Historical Prices
Date | Net Asset Value |
---|
Portfolio
Portfolio
Holding | Sector | Assets |
---|
The Rubicon Project, Inc. | Consumer Discretionary | 3.6% |
Cerence Inc | Information Technology | 3.2% |
Calix Networks, Inc. | Information Technology | 2.7% |
Agilysys Inc | Information Technology | 2.5% |
Digital Turbine Inc | Information Technology | 2.5% |
Eidos Therapeutics Inc | Health Care | 2.4% |
Cardlytics Inc | Information Technology | 2.0% |
Shockwave Medical Inc | Health Care | 1.9% |
Pacific Biosciences of California, Inc. | Health Care | 1.8% |
Telos Corp | Information Technology | 1.8% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Holding | Sector | Assets |
---|
Cerence Inc | Information Technology | 3.4% |
The Rubicon Project, Inc. | Consumer Discretionary | 3.2% |
Agilysys Inc | Information Technology | 2.8% |
Calix Networks, Inc. | Information Technology | 2.5% |
Digital Turbine Inc | Information Technology | 2.3% |
Cardlytics Inc | Information Technology | 2.2% |
Shockwave Medical Inc | Health Care | 2.1% |
Sprout Social Inc | Information Technology | 2.0% |
Select Comfort Corp. | Consumer Discretionary | 2.0% |
Eidos Therapeutics Inc | Health Care | 2.0% |
CryoPort Inc | Health Care | 1.9% |
Quanterix Corp | Health Care | 1.8% |
Chart Industries, Inc. | Industrials | 1.7% |
LGI Homes, Inc. | Consumer Discretionary | 1.7% |
Veracyte Inc | Health Care | 1.6% |
Axonics Modulation Technologies Inc | Health Care | 1.6% |
SI-BONE Inc | Health Care | 1.5% |
CEVA, Inc. | Information Technology | 1.5% |
elf Beauty, Inc. | Consumer Staples | 1.5% |
Trupanion Inc | Financials | 1.5% |
Ichor Holdings Ltd | Information Technology | 1.5% |
Malibu Boats, Inc. | Consumer Discretionary | 1.5% |
Inspire Medical Systems Inc | Health Care | 1.5% |
Trillium Therapeutics Inc | Health Care | 1.4% |
Myovant Sciences Ltd | Health Care | 1.4% |
OrthoPediatrics Corp | Health Care | 1.3% |
Spartan Motors, Inc. | Industrials | 1.3% |
Pacific Biosciences of California, Inc. | Health Care | 1.3% |
nLight Inc | Information Technology | 1.3% |
Telos Corp | Undefined | 1.3% |
Central Garden & Pet Co. | Consumer Staples | 1.3% |
Federal Home Loan Mortgage Corp. | Health Care | 1.2% |
Castle Biosciences Inc | Health Care | 1.2% |
CareDx Inc | Health Care | 1.2% |
Goosehead Insurance Inc | Financials | 1.2% |
Insmed, Inc. | Health Care | 1.2% |
Silk Road Medical Inc | Health Care | 1.2% |
NanoString Technologies, Inc. | Health Care | 1.2% |
Evoqua Water Technologies Corp | Industrials | 1.1% |
GenMark Diagnostics, Inc. | Health Care | 1.1% |
Montrose Environmental Group Inc | Industrials | 1.1% |
Rambus, Inc. | Information Technology | 1.0% |
Seres Therapeutics, Inc. | Health Care | 1.0% |
TG Therapeutics, Inc. | Health Care | 1.0% |
Beam Therapeutics Inc | Health Care | 1.0% |
Turning Point Therapeutics Inc | Health Care | 1.0% |
SPX Corp. | Industrials | 1.0% |
Crocs, Inc. | Consumer Discretionary | 1.0% |
Sonos Inc | Consumer Discretionary | 0.9% |
Scholar Rock Holding Corp | Health Care | 0.9% |
Duluth Holdings, Inc. | Consumer Discretionary | 0.9% |
Rocket Pharmaceuticals Inc | Health Care | 0.9% |
International Rectifier Corp. | Real Estate | 0.9% |
Atlas Air Worldwide Holdings, Inc. | Industrials | 0.8% |
Ameresco, Inc. | Industrials | 0.8% |
Upland Software Inc | Information Technology | 0.8% |
Karuna Therapeutics Inc | Health Care | 0.8% |
Simulations Plus Inc | Health Care | 0.8% |
Gentherm, Inc. | Consumer Discretionary | 0.8% |
Papa John's International, Inc. | Consumer Discretionary | 0.7% |
Celsius Holdings Inc | Consumer Staples | 0.7% |
Krystal Biotech Inc | Health Care | 0.7% |
National Vision Holdings Inc | Consumer Discretionary | 0.7% |
Health Catalyst Inc | Health Care | 0.7% |
Vital Farms Inc | Consumer Staples | 0.7% |
Stoke Therapeutics Inc | Health Care | 0.6% |
Inari Medical Inc | Health Care | 0.6% |
Federal Signal Corp. | Industrials | 0.6% |
fuboTV Inc | Information Technology | 0.6% |
Aurinia Pharmaceuticals Inc | Health Care | 0.6% |
RealReal Inc/The | Consumer Discretionary | 0.6% |
Pliant Therapeutics Inc | Health Care | 0.6% |
Ontrak Inc | Health Care | 0.6% |
Outset Medical Inc | Health Care | 0.6% |
Black Diamond Therapeutics Inc | Health Care | 0.6% |
Landcadia Holdings II Inc | Undefined | 0.6% |
Rush Enterprises, Inc. | Industrials | 0.5% |
Willdan Group Inc | Industrials | 0.5% |
Overstock.com, Inc. | Consumer Discretionary | 0.5% |
Limelight Networks, Inc. | Information Technology | 0.5% |
AudioCodes Ltd | Information Technology | 0.5% |
Adaptimmune Therapeutics plc | Health Care | 0.4% |
SVMK Inc | Information Technology | 0.3% |
Coherus Biosciences, Inc. | Health Care | 0.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 12/31/2020
Sector | Weighting | Fund Change from Previous Quarter |
---|
Sector | Weighting | Fund Change from Previous Quarter |
---|---|---|
Communication Services |
![]() |
|
Real Estate |
![]() |
|
Utilities | 0.0% | |
Not Classified |
![]() |
|
Consumer Discretionary |
![]() |
|
Consumer Staples |
![]() |
|
Energy | 0.0% | |
Financials |
![]() |
|
Health Care |
![]() |
|
Industrials |
![]() |
|
Information Technology |
![]() |
|
Materials | 0.0% |
Portfolio Details as of 12/31/2020
- Total Net Assets
- $189.29 M
- Number of Holdings
- 87
- Weighted Average Market Cap.
- 2.6 B
- P/B Ratio
- 6.9x
- Portfolio Turnover Ratio as of 10/31/2019
- 94.1%
- P/E Ratio
- 36.2x
To view definitions for the above Portfolio Details, Click here.
P/B Ratio - A ratio that helps determine whether a stock is undervalued or overvalued. It is calculated by dividing a stock's price per share by its book value per share. The result is based upon a weighted average of the securities held in the fund.
P/E Ratio - Is the weighted average of each holding's P/E ratio (price of a stock divided by its earnings per share). The result is based upon a weighted average of the securities held in the fund.
Weighted Average Market Cap - The average market capitalization of all companies held in the portfolio with each company weighted according to its percent held in the portfolio. The result is based upon a weighted average of the securities held in the fund.
Contributors & Detractors as of 12/31/2020
Contributors
Holding | Contribution |
---|---|
The Rubicon Project, Inc. | 4.2% |
Cerence Inc | 2.3% |
Eidos Therapeutics Inc | 2.0% |
Cardlytics Inc | 1.4% |
Digital Turbine Inc | 1.4% |
Detractors
Holding | Contribution |
---|---|
Overstock.com, Inc. | -0.5% |
Limelight Networks, Inc. | -0.4% |
Vital Farms Inc | -0.4% |
Duluth Holdings, Inc. | -0.2% |
Adaptimmune Therapeutics plc | -0.2% |
% Contribution reflects the effect of the individual stock's performance on the Fund's overall performance for the period. Individual holdings and their effect on Fund performance may change significantly over time. Investors should consider the overall performance of the Fund before making a decision on whether or not to invest in the Fund.
Attribution Analysis
Micro Cap Growth Fund | Benchmark | Variance | |||||
---|---|---|---|---|---|---|---|
Sector | Avg. Weight | Base Return | Avg. Weight | Base Return | Stock Selection | Group Weight | Total |
The total base return displayed for the Fund does not capture daily cash flow and trading activity and therefore is subject to reasonable variance from the Fund's actual return. Please refer to the Fund's performance results for longer-term returns. The Fund is actively managed and portfolio characteristics, such as individual holdings and sector weightings, may change significantly over time.
Source: Wilshire Attribution Software. GICS sector classification; non-GICS securities classified by Lord Abbett. Sectors may include many industries.
Dividends & Cap Gains
Dividends & Cap Gains
Dividend Payments
- YTD Dividends Paidas of 01/22/2021
- $0
- Dividend Frequency
- Annually
Record Date | Ex-Dividend Date | Reinvest & Payable Date | Dividend | Reinvest Price |
---|---|---|---|---|
11/20/2001 | 11/21/2001 | 11/21/2001 | $0.00740 | $10.09 |
Upcoming Dividend Payment Dates
This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.
Record Date | Ex-Dividend Date | Reinvest & Payable Date |
---|---|---|
11/22/2021 | 11/23/2021 | 11/23/2021 |
Capital Gains Distributions
Record Date | Reinvest & Payable Date | Long-term | Short-term * | Total | Reinvest Price |
---|---|---|---|---|---|
11/23/2020 | 11/24/2020 | $2.8043 | $2.2741 | $5.0784 | $15.43 |
Taxed as ordinary income
Lord Abbett does not provide tax advice. It is strongly recommended that you discuss the impact of dividends and distributions with your tax advisor.
Upcoming Capital Gain Distribution
This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.
Record Date | Ex-Dividend Date |
---|---|
11/22/2021 | 11/23/2021 |
Fees & Expenses
Fees & Expenses
Sales Charge Schedule as of 01/22/2021
Sales Charge | Dealer's Concession | Prices at Breakpoint | |
---|---|---|---|
Less than $50,000 | 5.75% | 5.00% | $22.03 |
$50,000 to $99,999 | 4.75% | 4.00% | $21.80 |
$100,000 to $249,999 | 3.95% | 3.25% | $21.61 |
$250,000 to $499,999 | 2.75% | 2.25% | $21.35 |
$500,000 to $999,999 | 1.95% | 1.75% | $21.17 |
$1,000,000 to $5,000,000 | 0.00% | 1.00% | $20.76 |
The 12b-1 trail commission is 0.15% (accrues immediately) for all fixed-income and municipal income funds.
Class A shares purchased without a sales charge (commissionable NAV) will be subject to a CDSC of 1% if they are redeemed before the first day of the month in which the one-year anniversary of the purchase falls.
Expense Ratioas of 12/31/2020
1.31% |
Fund Documents
Fund Documents
Download fund documents & literature, create email subscriptions, and place direct mail order
0Documents selected
|
Order | ||||
---|---|---|---|---|---|
n/a |
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
n/a |
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
Summary Prospectus
Publish Date:11/03/2015
|
|||||
n/a |
Statutory Prospectus
Publish Date:11/03/2015
|
||||
n/a |
Prospectus (XBRL)
Publish Date:11/03/2015
|
||||
SAI
Publish Date:11/03/2015
|
|||||
Annual Report
Publish Date:11/03/2015
|
|||||
Semi-Annual Report
Publish Date:11/03/2015
|
|||||
Fact Sheet
Publish Date:11/03/2015
|
|||||
Commentary
Publish Date:11/03/2015
|